N-甲基-4-(三氟甲氧基)苯胺 | 41419-59-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 中文名称: N-甲基-4-(三氟甲氧基)苯胺
• 中文别名: N-甲基对三氟甲氧基苯胺；N1-甲基-4-三氟甲氧基苯胺；N1-甲基-4-(三氟甲氧基)苯胺
• 英文名称: N-methyl-4-(trifluoromethoxy)aniline
• 英文别名: N-methyl-4-(trifluoromethoxy)benzenamine；methyl-(4-trifluoromethoxyphenyl)amine；4-(trifluoromethoxy)-N-methylaniline
• CAS: 41419-59-4
• 化学式: C₈H₈F₃NO
• mdl: MFCD00052332
• 分子量: 191.153
• InChiKey: MGCCWCLGIPNIBP-UHFFFAOYSA-N

物化性质

• 沸点：
  96 °C
• 密度：
  1.28g/ml
• 稳定性/保质期：

  常规情况下不会分解，也没有任何危险反应。

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  21.3
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 危险等级：
  TOXIC
• 危险品标志：
  T
• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R20/21/22,R36/37/38
• 海关编码：
  2922299090
• 包装等级：
  III
• 危险类别：
  6.1
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P310,P301+P312,P302+P352,P304+P340,P312,P321,P322,P330,P361,P363,P405,P501
• 危险品运输编号：
  2810
• 危险性描述：
  H301,H311,H332
• 储存条件：
  密封、阴凉、干燥保存。

SDS

Name:	N1-Methyl-4-(trifluoromethoxy)aniline 95+% Material Safety Data Sheet
Synonym:
CAS:	41419-59-4

Section 1 - Chemical Product MSDS Name:N1-Methyl-4-(trifluoromethoxy)aniline 95+% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
41419-59-4	N1-Methyl-4-(trifluoromethoxy)aniline	95+%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 41419-59-4: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Liquid
Color: colorless - pale yellow
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 96 - 98 deg C @15mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H8F3NO
Molecular Weight: 191

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Oxidizing agents, acids, acid chlorides.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide, fluorine, hydrogen fluoride gas.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 41419-59-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
N1-Methyl-4-(trifluoromethoxy)aniline - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 41419-59-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 41419-59-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 41419-59-4 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  N-甲基-4-(三氟甲氧基)苯胺 在 哌啶 、 Co(dmgH)(dmgH₂)Cl₂ 、 (4,4'-di-tert-butyl-2,2'-dipyridyl)-bis-(2-phenylpyridine(-1H))-iridium(III) hexafluorophosphate 作用下， 以 乙腈 为溶剂， 反应 24.0h， 以73%的产率得到对三氟甲氧基苯胺
  参考文献：
  名称：

  反向电子转移的最小化使得仲苯胺难以捉摸的 sp3 C−H 官能化

  摘要：

  苯胺是光诱导电子转移中最常用的一类底物。 N,N-二烷基衍生物能够通过氧化然后去质子化使 N 原子产生自由基 α。然而，由于快速反电子转移（BET），这种方法对于单取代苯胺来说难以捉摸。在这里，我们证明了在外源烷基胺存在的情况下使用光氧化还原催化可以最大限度地减少 BET。这种方法协同帮助苯胺 SET 氧化，然后加速随后的去质子化。通过这种方式，现在可以生成 α-苯胺烷基自由基，并且这些物质可以在一般意义上用于实现不同的 sp 3 C−H 官能化。

  DOI：

  10.1002/anie.202100051
• 作为产物：
  描述：

  对三氟甲氧基苯胺 在 吡啶 、 二氢吡啶 、 potassium tert-butylate 作用下， 以 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 19.0h， 生成 N-甲基-4-(三氟甲氧基)苯胺
  参考文献：
  名称：

  无过渡金属和可见光介导的脱磺酰化和脱卤反应：Hantzsch酯阴离子作为电子和氢原子供体。

  摘要：

  已开发出在室温（rt）和无过渡金属条件下进行N-和O-磺酰化的新方法。第一种方法涉及在室温下仅使用二甲基亚砜（DMSO）中的KO t Bu将各种N-磺酰基杂环和苯基苯磺酸盐以良好或优异的收率转化为相应的脱磺酰化产物。或者，已经使用可见光方法用作为可见光吸收剂的Hantzsch酯（HE）阴离子和电子和氢原子供体来促进N-甲基-N-芳基磺酰胺的脱保护，以促进脱磺酰化反应。HE阴离子可轻松就地制备通过在室温下将相应的HE与DMSO中的KO t Bu反应。进一步研究了两种方案的合成范围和机制方面，以合理化脱磺酰化工艺的关键特征。此外，HE阴离子在可见光照射下诱导芳基卤化物的还原脱卤反应。

  DOI：

  10.1021/acs.joc.0c01523

文献信息

• NEW HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES
  申请人：Ackermann Jean

  公开号：US20110065707A1

  公开（公告）日：2011-03-17

  The present invention relates to compounds of formula (I) as well as pharmaceutically acceptable salts thereof, wherein A 1 , A 2 , R 1 , R 2 , R 3 , R 4 , R 5 and R 6 have the significance given herein.

  本发明涉及式(I)的化合物以及其药学上可接受的盐，其中A1、A2、R1、R2、R3、R4、R5和R6具有本文中给出的含义。
• [EN] HSL INHIBITORS USEFUL IN THE TREATMENT OF DIABETES<br/>[FR] INHIBITEURS DE HSL UTILES DANS LE TRAITEMENT DU DIABÈTE
  申请人：HOFFMANN LA ROCHE

  公开号：WO2011029808A1

  公开（公告）日：2011-03-17

  Compounds of formula (I), as well as pharmaceutically acceptable salts thereof can be used in the form of pharmaceutical compositions, wherein A1, A2, R1,R2 R3,R4 R5 and R6 have the significance given in claim 1. Objects of the present invention are the compounds of formula (I) and their aforementioned salts and esters and their use as therapeutically active substances, a process for the manufacture of the said compounds, intermediates, pharmaceutical compositions, medicaments containing the said compounds, their pharmaceutically acceptable salts or esters, the use of the said compounds, salts or esters for the treatment or prophylaxis of illnesses, especially in the treatment or prophylaxis of diabetes, metabolic syndrome, dyslipidemia, atherosclerosis or obesity and the use of the said compounds, salts or esters for the production of medicaments for the treatment or prophylaxis of diabetes, metabolic syndrome, dyslipidemia, atherosclerosis or obesity.

  化合物的化学式（I），以及其药学上可接受的盐可以用作药物组合物的形式，其中A1，A2，R1，R2，R3，R4，R5和R6具有权利要求1中给定的含义。本发明的目的是化学式（I）的化合物及其上述的盐和酯，以及它们作为治疗活性物质的用途，制造所述化合物的方法，中间体，含有所述化合物的药物组合物，含有所述化合物、其药学上可接受的盐或酯的药物，所述化合物、盐或酯的用途用于治疗或预防疾病，特别是用于治疗或预防糖尿病、代谢综合征、血脂异常、动脉粥样硬化或肥胖症，以及所述化合物、盐或酯的用途用于生产用于治疗或预防糖尿病、代谢综合征、血脂异常、动脉粥样硬化或肥胖症的药物。
• Electrochemical <i>N</i>-Formylation of Amines via Decarboxylation of Glyoxylic Acid
  作者：Dian-Zhao Lin、Jing-Mei Huang

  DOI：10.1021/acs.orglett.8b00698

  日期：2018.4.6

  A new method for the synthesis of formamides has been developed through electrochemical decarboxylative N-formylation of amines with glyoxylic acid. This protocol provides an efficient approach to formamides with a broad range of functional group tolerance under ambient conditions.

  通过用乙醛酸对胺进行电化学脱羧N-甲酰化，已开发出一种新的甲酰胺合成方法。该协议为环境条件下具有宽泛的官能团耐受性的甲酰胺提供了一种有效的方法。
• Substituted N, N-disubstituted diamino compounds useful for inhibiting cholesteryl ester transfer protein activity
  申请人：——

  公开号：US20020120011A1

  公开（公告）日：2002-08-29

  The invention relates to substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamine compounds useful as inhibitors of cholesteryl ester transfer protein (CETP; plasma lipid transfer protein-I) and compounds, compositions and methods for treating atherosclerosis and other coronary artery diseases. Preferred tertiary-heteroalkylamine compounds are substituted N,N-disubstituted diamines. A preferred specific N,N-disubstituted diamine is the compound: 1

  这项发明涉及替代多环芳基和杂环芳基的三级杂烷基胺化合物，可用作胆固醇酯转移蛋白（CETP；血浆脂质转移蛋白-I）的抑制剂，以及用于治疗动脉粥样硬化和其他冠状动脉疾病的化合物、组合物和方法。首选的三级杂烷基胺化合物是取代的N,N-二取代二胺。首选的具体N,N-二取代二胺化合物是：1
• [EN] GROUP 5 METAL COMPLEXES FOR CATALYTIC AMINE FUNCTIONALIZATION<br/>[FR] COMPLEXES MÉTALLIQUES DU GROUPE 5 POUR LA FONCTIONNALISATION CATALYTIQUE D'AMINE
  申请人：UNIV BRITISH COLUMBIA

  公开号：WO2018213938A1

  公开（公告）日：2018-11-29

  This application pertains to group 5 metal complexes having the structure of Formula I; and their potential utility in catalyzing α-alkylation of secondary amine-containing moieties.

  这种应用涉及具有公式I结构的5族金属配合物；以及它们在催化含有次要胺基团的α-烷基化中的潜在用途。